12.14.09
Charles Bancroft has been appointed acting chief financial officer of Bristol-Myers Squibb, effective January 1, 2010. Jean-Marc Huet, executive vice president and chief financial officer, will leave the company at the end of 2009.
“Jean-Marc has indicated to me his desire to return to Europe and we wish him every success,” said James M. Cornelius, chairman and chief executive officer of BMS. “The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which have greatly accelerated our BioPharma transformation.”
Mr. Bancroft was most recently vice president, finance for BMS's global biopharmaceutical business. In his new role, he will continue to report to Lamberto Andreotti, president and chief operating officer.
Mr. Bancroft joined the company in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec.
“Jean-Marc has indicated to me his desire to return to Europe and we wish him every success,” said James M. Cornelius, chairman and chief executive officer of BMS. “The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which have greatly accelerated our BioPharma transformation.”
Mr. Bancroft was most recently vice president, finance for BMS's global biopharmaceutical business. In his new role, he will continue to report to Lamberto Andreotti, president and chief operating officer.
Mr. Bancroft joined the company in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec.